MedWatch

Big investments in Danish life science industry make 2021 historic year for raising capital

In 2021, Danish life science firms have brought in record sums and next year is looking even better, several venture funds assess. However, renewed Covid-19 fears, bubble tendencies and – paradoxically – current year's big investments may prove roadblocks for next year's promises.

Photo: Photo: Pexels: Martin Lopez.

In the year coming to an end soon, millions upon millions of Danish kroner have poured into a number of Danish life science firms to such a degree that 2021 has become the best year for raising capital in the domestic industry ever.

This is apparent just a few days before the clocks strike midnight on New Year's Eve, welcoming a 2022 that has the potential to become another record-breaking year for the Danish life science industry, though some dangers and wildcards loom on the horizon.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Further reading

Related articles

Latest news

See all jobs